Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study

Ichiei Narita, Terumasa Hayashi, Shoichi Maruyama, Takao Masaki, Masaomi Nangaku, Tomoya Nishino, Hiroshi Sato, Tadashi Sofue, Takashi Wada, Enyu Imai, Manabu Iwasaki, Kyoichi Mizuno, Hiroki Hase, Masahiro Kamouchi, Hiroyasu Yamamoto, Tatsuo Kagimura, Kenichiro Tanabe, Hideki Kato, Takehiko Wada, Tomoko UsuiTadao Akizawa, Hideki Hirakata, Yoshiharu Tsubakihara

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Among non-dialysis-dependent chronic kidney disease (ND-CKD) patients, a low hematopoietic response to erythropoiesis-stimulating agents (ESAs) is a predictor for poor renal and cardiovascular outcome. To assess the method for evaluating hyporesponsiveness to ESA in patients with ND-CKD, a multicenter, prospective, observational study of 1,980 adult patients with ND-CKD with renal anemia was conducted. Darbepoetin alfa (DA) and iron supplement administrations were provided according to the recommendation of the attached document and the guidelines of JSDT (Japanese Society of Dialysis and Transplantation). The primary outcomes were progression of renal dysfunction and major adverse cardiovascular events. ESA responsiveness was assessed using pre-defined candidate formulae. During the mean follow-up period of 96 weeks, renal and cardiovascular disease (CVD) events occurred in 683 (39.6%) and 174 (10.1%) of 1,724 patients, respectively. Among pre-set candidate formulae, the one expressed by dividing the dose of DA by Hb level at the 12-week DA treatment was statistically significant in predicting renal (hazard ratio [HR], 1.449; 95% confidence interval [CI], 1.231–1.705; P<0.0001) and CVD events (HR, 1.719; 95% CI, 1.239–2.386; P = 0.0010). The optimum cut-off values for both events were close to 5.2. In conclusion, hyporesponsiveness to ESA in ND-CKD cases, which is associated with a risk for renal and CVD events, may be evaluated practicably as the dose of DA divided by the Hb level at the 12-week DA treatment, and the cut-off value of this index is 5.2. A search for the causes of poor response and measures for them should be recommended in such patients.

Original languageEnglish
Article numbere0277921
JournalPloS one
Issue number11 November
Publication statusPublished - Nov 2022
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study'. Together they form a unique fingerprint.

Cite this